ReviewJournal of physiology and biochemistry2026
Roles of extracellular vesicles in the pathogenesis of chronic myeloid leukemia.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The recent progression of extracellular vesicles application in osteoporosis.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are lipid bilayer-enclosed particles released by cells into the extracellular space. They are produced by the majority of cell types under both physiological and pathological conditions. EVs mediate intercellular communication by delivering bioactive molecules - such as RNAs, adhesion molecules, signaling mediators, and antigen-presenting molecules - to recipient cells, thereby modulating their phenotype and function. A growing body of evidence highlights the involvement of EVs in the pathophysiology of leukemia, including their roles in remodeling the bone marrow microenvironment, promoting angiogenesis, enabling immune evasion, regulating apoptosis, and contributing to drug resistance. Beyond their functional roles, EVs are emerging as promising diagnostic and prognostic biomarkers, as well as potential drug delivery vehicles. This review first outlines key aspects of chronic myeloid leukemia and the bone marrow niche, and then focuses on the current understanding of how EVs contribute to the transformation of a normal bone marrow environment into a leukemic one. Finally, we discuss the potential applications of EVs as biomarkers and therapeutic delivery systems in chronic myeloid leukemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.